View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 28, 2022

Two booster trials to evaluate Novavax’s protein-based Covid-19 vaccine

The NVX-CoV2373 vaccine will be assessed as a booster in a NIAID-sponsored Phase I/II trial and a Phase III trial in the UAE.

Novavax has reported that its protein-based Covid-19 vaccine, NVX-CoV2373, will be included in two clinical trials to analyse it as a booster.

Created from the initial strain of the SARS-CoV-2 virus’ genetic sequence, the vaccine has a purified protein antigen.

Furthermore, it is formulated with a saponin-based Matrix-M adjuvant of the company to boost immune response and induce increased neutralising antibody levels.

The ongoing studies have initiated subject enrolment and will analyse the safety, immunogenicity and reactogenicity of the vaccine.

They are intended to expand knowledge of how various vaccines, including Novavax’s NVX-CoV2373, can be used for boosting after an initial vaccine regimen.

A National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Phase I/II trial is underway to evaluate homologous and heterologous boosting regimens in subjects who have previously received a primary vaccine regimen.

The vaccines used in the initial vaccine series have obtained approval or emergency use authorization (EUA) from the US Food and Drug Administration (FDA).

In this trial, subjects will receive a third dose of either NVX-CoV2373 or any of the three FDA-authorised or -approved Covid-19 vaccines after more than 12 weeks.

Carried out at around ten study centres, the trial will have approximately 1,130 healthy subjects aged 18 years or above, with nearly 180 of them receiving the Novavax vaccine as a heterologous booster.

Assessing the safety, reactogenicity and immunogenicity of delayed heterologous or homologous vaccine doses following EUA vaccines are the primary objectives of the trial.

Subjects will be followed up for a year and topline data and full findings from the trial are anticipated later this year and next year, respectively.

The second study of Novavax’s vaccine, being carried out in the United Arab Emirates (UAE), is an observer-blinded Phase III trial.

It will analyse homologous versus heterologous boosting of subjects previously vaccinated with Sinopharm’s Covid-19 vaccine.

In this study, safety and immunogenicity following boosting with a single dose of Novavax’s vaccine in previously inoculated adults will be studied. 

It will enrol nearly 1,000 subjects of age 18 years or above at two sites in Abu Dhabi, UAE, who will be followed up for six months.

Full data from this trial is expected in the fourth quarter of this year. 

Novavax chief medical officer Filip Dubovsky said: “Our Covid-19 vaccine has already been recommended by multiple national policy bodies for both primary vaccination and booster settings in individuals 18 years of age and older.

“We look forward to adding to this body of evidence to support the expanded use of our protein-based vaccine.”

In February, the company reported that NVX-CoV2373 met the primary immunogenicity endpoint in the paediatric expansion of its Phase III PREVENT-19 trial.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU